# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and ann...
Calidi and SIGA are partnering in order to advance Calidi's RTNova virotherapy for lung cancer and metastatic solid tumors.